Dieleman JP - Search Results

1

[Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects].

Tempelman C, Timmermans S, Godfried MH, Dieleman JP, Boer K, van der Ende ME. Tempelman C, et al. Among authors: dieleman jp. Ned Tijdschr Geneeskd. 2004 Oct 9;148(41):2021-5. Ned Tijdschr Geneeskd. 2004. PMID: 15553999 Dutch.

2

Nelfinavir and nevirapine side effects during pregnancy.

Timmermans S, Tempelman C, Godfried MH, Nellen J, Dieleman J, Sprenger H, Schneider ME, de Wolf F, Boer K, van der Ende ME; Dutch HMF Study Group. Timmermans S, et al. AIDS. 2005 May 20;19(8):795-9. doi: 10.1097/01.aids.0000168973.59466.14. AIDS. 2005. PMID: 15867493

3

[Treatment adherence amongst HIV-infected patients in Rotterdam: poorer prognosis independent of nationality in heterosexual infected patients, intravenous drug users, Negroid and Latin-American patients].

Kooiman EL, Dieleman JP, Gyssens IC, Nieuwkerk PT, de Marie S, van der Ende ME. Kooiman EL, et al. Among authors: dieleman jp. Ned Tijdschr Geneeskd. 2002 Jun 22;146(25):1183-7. Ned Tijdschr Geneeskd. 2002. PMID: 12109310 Dutch.

4

[Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors].

Dieleman JP, Hillebrand-Haverkort ME, van der Ende ME, Sturkenboom MC, Lange JM, Stricker BH. Dieleman JP, et al. Ned Tijdschr Geneeskd. 1998 Dec 26;142(52):2856-60. Ned Tijdschr Geneeskd. 1998. PMID: 10065260 Dutch.

5

Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population.

de Vries-Sluijs TE, Dieleman JP, Arts D, Huitema AD, Beijnen JH, Schutten M, van der Ende ME. de Vries-Sluijs TE, et al. Among authors: dieleman jp. Clin Pharmacokinet. 2003;42(6):599-605. doi: 10.2165/00003088-200342060-00009. Clin Pharmacokinet. 2003. PMID: 12793844

6

Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients.

Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM. Dieleman JP, et al. AIDS. 1999 Mar 11;13(4):473-8. doi: 10.1097/00002030-199903110-00005. AIDS. 1999. PMID: 10197375

7

Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression.

Dieleman JP, Sturkenboom MC, Wit FW, Jambroes M, Mulder JW, Ten Veen JH, Juttmann J, Stricker BH, Lange JM, Van Der Ende ME; AIDS Therapy Evaluation, The Netherlands Study Group (ATHENA). Dieleman JP, et al. J Infect Dis. 2002 May 1;185(9):1261-8. doi: 10.1086/340131. Epub 2002 Apr 16. J Infect Dis. 2002. PMID: 12001043

8

Low prevalence of cardiac abnormalities in an HIV-seropositive population on antiretroviral combination therapy.

Bijl M, Dieleman JP, Simoons M, van der Ende ME. Bijl M, et al. Among authors: dieleman jp. J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):318-20. doi: 10.1097/00126334-200107010-00018. J Acquir Immune Defic Syndr. 2001. PMID: 11464156 No abstract available.

9

Papillary necrosis associated with the HIV protease inhibitor indinavir.

Dieleman JP, van der Feltz M, Bangma CH, Stricker BH, van der Ende ME. Dieleman JP, et al. Infection. 2001 Aug;29(4):232-3. doi: 10.1007/s15010-001-1105-y. Infection. 2001. PMID: 11545487

10

A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).

Burger DM, Aarnoutse RE, Dieleman JP, Gyssens IC, Nouwen J, de Marie S, Koopmans PP, Stek M Jr, van der Ende ME. Burger DM, et al. Among authors: dieleman jp. Antivir Ther. 2003 Oct;8(5):455-61. Antivir Ther. 2003. PMID: 14640393 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

117 results

Search Page